. First‑line chemoimmunotherapy is currently a standard treatment for extensive‑stage small cell lung cancer (ES‑SCLC), but the value of immune checkpoint inhibitor (ICI)‑based subsequent treatment after progression remains uncertain. The present meta‑analysis assessed the efficacy and safety of ICI‑based vs. non‑immun...
Chuan Long, Ying-Ding Ruan, Ai-Ming Yang et al.· Oncology Letters· 0 citations
Findings support timely completion of definitive radiotherapy and indicate that the 56-day interval remains a clinically relevant benchmark for cervical cancer.
Ying-Ding Ruan, Yun Li, Dan Wu et al.· Frontiers in Oncology· 0 citations
Osimertinib is the standard first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), but outcomes remain heterogeneous. This meta-analysis evaluated baseline clinical and molecular prognostic factors associated with poorer outcomes in this setting. PubMed, Emba...
Ying-Ding Ruan, Hong-Sheng Xue, Chuan Long et al.· BMC Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.